Details of a Researcher - Yonezawa, Atsushi

Papers - Yonezawa, Atsushi

Division display 1 - 20 of about 150 ／ All the affair displays >>

Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study.

Takashi Masuda, Taro Funakoshi, Takahiro Horimatsu, Sho Masui, Daiki Hira, Marin Inoue, Kodai Yajima, Shunsaku Nakagawa, Yasuaki Ikemi, Junzo Hamanishi, Atsushi Takai, Shinya Yamamoto, Takeshi Matsubara, Masaki Mandai, Hiroshi Seno, Motoko Yanagita, Manabu Muto, Tomohiro Terada, Atsushi Yonezawa

Cancer chemotherapy and pharmacology 95 ( 1 ) 46 - 46 2025.12

Research paper (scientific journal), Joint Work, Last author, Corresponding author, Accepted, ISSN 03445704

PURPOSE: Bevacizumab (BV) is an effective therapeutic antibody utilized in various cancers. Serum BV concentration can be a factor that potentially affects its therapeutic efficacy. Although proteinuria could affect BV pharmacokinetics, its influence was not evaluated in the previous population pharmacokinetic (PopPK) studies. Because BV can cause proteinuria as an adverse event, the present study aimed to develop a PopPK model in patients with proteinuria and to evaluate the influence of proteinuria on BV pharmacokinetics. METHODS: This prospective cohort study enrolled 70 Japanese cancer patients newly starting BV, and 368 concentration samples from these patients were analyzed. Serum BV concentrations were measured at several time points including at the onset of proteinuria. PopPK analysis was conducted using a non-linear mixed-effects modeling program. A two-compartment model was used to estimate total body clearance (CL). RESULTS: Serum BV concentrations divided by the dose per body weight and dosing interval tended to be lower in patients with higher urinary protein to creatinine ratio (UPCR). The covariate analysis showed that increasing BV CL was associated with decreasing serum albumin concentration and increasing body weight and UPCR. The simulated median trough concentrations of BV in patients with Common Terminology Criteria for Adverse Events grades 1, 2, and 3 proteinuria were decreased by 12.0%, 20.6%, and 31.5%, respectively, compared to those in patients with grade 0. CONCLUSION: We successfully established a PopPK model incorporating UPCR to predict serum BV concentrations in patients with proteinuria. Our study provides additional insights to better understand BV pharmacokinetics.

病院薬剤師に対する外来がん治療患者のニーズに関するアンケート調査　病院薬剤師へのタスク・シフト/シェアに向けての考察

杉本充弘, 米澤淳, 池見泰明, 幾田慧子, 岡田浩, 眞中章弘, 長縄華子, 西郷雅美子, 小川晃宏, 飯原大稔, 三宅知宏, 鈴木昭夫, 寺田智祐

医療薬学 ((一社)日本医療薬学会) 51 ( 10 ) 605 - 613 2025.10

Research paper (scientific journal), Joint Work, Accepted, ISSN 1346-342X

Identification and Physiological Analysis of Novel Riboflavin Transporter RFVT

Yonezawa Atsushi

Biological and Pharmaceutical Bulletin (The Pharmaceutical Society of Japan) 48 ( 7 ) 951 - 956 2025.07

Lead author, Last author, Corresponding author, Accepted, ISSN 09186158

<p>Riboflavin (vitamin B2) is an essential water-soluble vitamin that serves as a precursor for flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN), key cofactors in biological redox reactions. These reactions are crucial for energy metabolism and cellular homeostasis. Mammals cannot synthesize riboflavin and rely on specialized transport systems for its absorption and distribution. The discovery of the riboflavin transporter (RFVT) family, comprising RFVT1 (SLC52A1), RFVT2 (SLC52A2), and RFVT3 (SLC52A3) has provided critical insights into riboflavin homeostasis. These transporters show tissue-specific expression and play essential roles in riboflavin uptake. Mutations in SLC52A2 and SLC52A3 have been linked to Brown–Vialetto–Van Laere syndrome (BVVLS), a rare neurodegenerative disorder characterized by progressive sensorineural hearing loss and cranial nerve dysfunction. Functional studies using knockout mouse models have demonstrated that Rfvt deficiency results in embryonic lethality or severe neurological impairment due to impaired riboflavin transport. Patients with BVVLS and RFVT mutations showed symptomatic improvement with high-dose riboflavin supplementation. This review summarizes the molecular characteristics, physiological functions, and pathological implications of RFVTs and emphasizes their role in disease mechanisms and potential therapeutic strategies. Understanding the riboflavin transport mechanisms provides a foundation for developing targeted treatments for riboflavin-related disorders.</p>

Effectiveness of posaconazole as primary prophylaxis in allogeneic hematopoietic stem cell transplantation

Hanyu Y., Kanda J., Sugimoto M., Iwasaki M., Watanabe M., Arai Y., Mizumoto C., Kitawaki T., Yamashita K., Yamagiwa T., Taniguchi R., Nakagawa S., Yonezawa A., Terada T., Takaori-Kondo A.

International Journal of Hematology 2025

Research paper (scientific journal), Joint Work, Accepted, ISSN 09255710

We retrospectively analyzed the effectiveness of posaconazole (tablet and infusion formulations) and its correlation with blood concentration in preventing invasive fungal infections (IFIs) in 360 patients who underwent allogeneic hematopoietic stem cell transplant (allo-HSCT) between 2010 and 2023. A total of 61 patients received posaconazole, 102 received micafungin, and 197 received fluconazole for primary prophylaxis. By day 100 post-transplant, the cumulative incidence of IFIs was significantly lower with posaconazole (5.0%) compared with fluconazole (14.4%) or micafungin (16.9%). Multivariate analysis showed that the risk of IFIs was significantly higher with fluconazole/micafungin than with posaconazole (hazard ratio 4.04, 95% CI 1.17–13.94, P = 0.027). This difference was most notable among patients with lymphoid malignancies (P = 0.053) and those undergoing repeat transplantation (P = 0.024). There were no significant differences in overall survival, non-relapse mortality, or mortality from IFI. Mean blood levels of posaconazole dropped to 0.57 μg/mL two weeks after allo-HSCT, coinciding with the observation of most IFIs in the posaconazole group shortly after transplant. Posaconazole appears to be more effective than fluconazole or micafungin as primary prophylaxis against IFIs in allo-HSCT recipients.

Access to Document (DOI)

Development of extended pharmacokinetic models for propofol based on measured blood and brain concentrations.

Masayoshi Kawata, Atsushi Yonezawa, Yohei Mineharu, Kotaro Itohara, Toshiyuki Mizota, Yoshihiro Matsui, Takayuki Kikuchi, Yukihiro Yamao, Etsuko Yamamoto Hattori, Miho Hamada, Daiki Hira, Keiko Furukawa, Susumu Miyamoto, Tomohiro Terada, Kazuo Matsubara, Yoshiki Arakawa

Scientific reports (Scientific Reports) 14 ( 1 ) 6326 - 6326 2024.12

Research paper (scientific journal), Joint Work, Corresponding author, Accepted, ISSN 2045-2322

Propofol's pharmacokinetics have been extensively studied using human blood samples and applied to target-controlled infusion systems; however, information on its concentration in the brain remains scarce. Therefore, this study aimed to simultaneously measure propofol plasma and brain concentrations in patients who underwent awake craniotomy and establish new pharmacokinetic model. Fifty-seven patients with brain tumors or brain lesions who underwent awake craniotomy were sequentially assigned to model-building and validating groups. Plasma and brain (lobectomy or uncapping margins) samples were collected at five time-points. The concentration of propofol was measured using high-performance liquid chromatography. Population pharmacokinetic analysis was conducted through a nonlinear mixed-effects modeling program using a first-order conditional estimation method with interactions. Propofol's brain concentrations were higher than its plasma concentrations. The measured brain concentrations were higher than the effect site concentrations using the previous models. Extended models were constructed based on measured concentrations by incorporating the brain/plasma partition coefficient (Kp value). Extended models showed good predictive accuracy for brain concentrations in the validating group. The Kp value functioned as a factor explaining retention in the brain. Our new pharmacokinetic models and Kp value can predict propofol's brain and plasma concentrations, contributing to safer and more stable anesthesia.

Access to Document (DOI)

Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease

Amano T., Yoshihara T., Shinzaki S., Sakakibara Y., Yamada T., Osugi N., Hiyama S., Murayama Y., Nagaike K., Ogiyama H., Yamaguchi T., Arimoto Y., Kobayashi I., Kawai S., Egawa S., Kizu T., Komori M., Tsujii Y., Asakura A., Tashiro T., Tani M., Otake-Kasamoto Y., Uema R., Kato M., Tsujii Y., Inoue T., Yamada T., Kitamura T., Yonezawa A., Iijima H., Hayashi Y., Takehara T.

Scientific Reports 14 ( 1 ) 29755 2024.12

Research paper (scientific journal), Joint Work, Accepted, ISSN 2045-2322

Serum leucine-rich alpha-2 glycoprotein (LRG) can monitor disease activities during biologics treatment in patients with inflammatory bowel disease (IBD). It is unclear whether the pretreatment serum LRG level can predict clinical effectiveness including serum trough levels of ustekinumab in patients with IBD. This multicenter prospective cohort study included 184 patients (Crohn’s disease, 104; ulcerative colitis, 80) who received ustekinumab (n = 119) or anti-tumor necrosis factor (n = 65) between January 2019 and March 2023. Multivariate logistic regression analysis revealed serum LRG level at week 0 (0w-LRG, odds ratio 0.12, 95% confidence interval 0.02–0.68) as one of significant factors for clinical remission at week 8. We divided patients into the low- and the high-LRG groups by the median 0w-LRG (18.2 µg/mL) and compared the effectiveness. In patients who received ustekinumab, the proportion of clinical remission at week 8 was significantly different between in the low- (76.9%) and in the high-LRG group (59.3%, P = 0.038), and median serum trough level at week 8 was significantly different between in the low- (10.9 µg/mL, interquartile range 6.7–13.4) and the high-LRG group (5.3 µg/mL, interquartile range 2.4–8.3, P < 0.001). The 0w-LRG can predict the effectiveness including serum trough levels of ustekinumab during induction treatment for patients with IBD.

Access to Document (DOI)

Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study

Mari Yokoi, Atsushi Yonezawa, Daiki Hira, Tomohiro Handa, Kiminobu Tanizawa, Shunsaku Nakagawa, Masahiro Tsuda, Yasuaki Ikemi, Ryo Itotani, Hironori Yoshida, Motoo Nomura, Junichi Matsubara, Kosaku Murakami, Hiroaki Ozasa, Manabu Muto, Tomohiro Terada

Journal of Pharmaceutical Health Care and Sciences (Springer Science and Business Media LLC) 10 ( 1 ) 52 2024.12

Research paper (scientific journal), Joint Work, Corresponding author, Accepted, ISSN 2055-0294

Abstract

Background

Interstitial lung disease (ILD) is one of the most common fatal immune-related adverse events (irAEs). ILD development adversely affects the continuation of anticancer drug therapy, including immune checkpoint inhibitor (ICI) therapy and prognosis. There are no established useful clinical indicators for the early detection of ILD. Furthermore, the factors that lead the attending physician to suspect ICI-induced ILD (ICI-ILD) remain unclear. This study aimed to investigate the ICI-ILD detection based on subjective symptoms and their relationship with disease severity in patients receiving anti-PD-1/PD-L1 antibody.

Methods

This was a retrospective observational study. We enrolled the patients who received anti-PD-1/PD-L1 antibody at Kyoto University Hospital between September 2014 and April 2021. Patients who developed ICI-ILD were stratified into two distinct groups based on factors that triggered the suspicion of ILD development. The “Subjective symptoms” group was defined as patients in whom ILD was detected based on subjective symptoms. Conversely, the “Routine examinations” group was defined as patients in whom ILD was suspected based on scheduled routine examinations. The severity of ILD in each group was assessed and its association with changes in the respiratory symptoms was examined.

Results

Of 926 patients who received anti-PD-1/PD-L1 antibody, 51 patients (5.5%) developed ICI-ILD. The incidence of ICI-ILD in patients with lung cancer was significantly higher than that in patients with other cancers (P < 0.001). Among the patients with ICI-ILD, 27 patients (52.9%) were classified into the “Subjective symptoms” group. The “Subjective symptoms” group exhibited a significantly higher proportion of Grade 3–5 ICI-ILD cases than the “Routine examinations” group (76.2% vs. 23.8%, P = 0.010). At the last visit, before the suspected onset of ILD, 21 of the 27 patients (77.8%) had no symptoms or no change in the respiratory symptoms.

Conclusion

Subjective symptoms triggered the suspicion of Grade 3–5 ICI-ILD. Enhanced monitoring and patient education could be essential for the early detection of ICI-ILD because ILD may develop rapidly. Our findings might help to manage ICI-ILD in clinical practice.

Access to Document (DOI)

Population Pharmacokinetic Modeling of Posaconazole in Japanese Patients Receiving Fungal Prophylaxis.

Mitsuhiro Sugimoto, Atsushi Yonezawa, Junya Kanda, Kotaro Itohara, Daiki Hira, Takeo Yamagiwa, Risa Taniguchi, Yuta Hanyu, Mizuki Watanabe, Yasuyuki Arai, Chisaki Mizumoto, Toshio Kitawaki, Tadakazu Kondo, Kouhei Yamashita, Akifumi Takaori-Kondo, Tomohiro Terada

Therapeutic drug monitoring 46 ( 5 ) 611 - 618 2024.04

Research paper (scientific journal), Joint Work, Corresponding author, Accepted, ISSN 0163-4356

BACKGROUND: Posaconazole is a vital drug to treat and prevent invasive fungal infections. Several factors, such as sex, body weight, total serum proteins, dietary intake, and severe mucositis, affect posaconazole pharmacokinetics (PKs). However, the relevance of other factors that affect the PKs of posaconazole in hematopoietic stem cell transplantation (HSCT) is unknown. This study explored factors influencing the PKs of posaconazole in HSCT recipients and nontransplant patients with hematological diseases. METHODS: The authors conducted a single-institution, retrospective study. Forty-two Japanese inpatients receiving oral posaconazole tablets as prophylaxis for fungal infections were enrolled in this study. A one-compartment model with first-order absorption was used as the structural pharmacokinetic model. A population PK (PopPK) analysis was performed using a nonlinear mixed-effects modeling program, using a first-order conditional estimation method with interactions. Perl-speaks-NONMEM and R were used to evaluate the goodness of fit and visualize the output. RESULTS: In 29% of the enrolled patients, the serum concentration of posaconazole was <0.5 mcg/mL, considered the effective range. PopPK analysis revealed that the patient had undergone HSCT within 1 year, diarrhea occurred more than 5 times a day, and aspartate aminotransferase were covariates that influenced apparent clearance (CL/F). The CL/F of posaconazole was 1.43-fold higher after HSCT and 1.26-fold higher during diarrhea. CONCLUSIONS: PopPK analysis revealed that HSCT, diarrhea, and aspartate aminotransferase were factors associated with the CL/F of posaconazole. The trough concentration of posaconazole may be below the therapeutic range in a few patients with diarrhea and/or after HSCT. As invasive fungal infections in patients with hematologic diseases can be life-threatening, therapeutic drug monitoring of posaconazole is strongly recommended, and patients should be carefully monitored.

Access to Document (DOI)

Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort.

Tomoya Kawakami, Sho Masui, Akira Onishi, Hideo Onizawa, Takayuki Fujii, Kosaku Murakami, Koichi Murata, Masao Tanaka, Takashi Shimada, Shunsaku Nakagawa, Shuichi Matsuda, Akio Morinobu, Tomohiro Terada, Atsushi Yonezawa

Modern rheumatology 34 ( 6 ) 1135 - 1141 2024.03

Research paper (scientific journal), Joint Work, Last author, Corresponding author, Accepted, ISSN 1439-7595

OBJECTIVES: Biosimilars are anticipated to be widely used in the treatment of rheumatoid arthritis (RA), owing to their cost efficiency; LBEC0101 was the first etanercept (ETN) biosimilar approved in Japan. However, there are limited real-world data comparing its safety and effectiveness with those of a reference product. METHODS: This study used data from the Kyoto University Rheumatoid Arthritis Management Alliance cohort, including patients with RA who received ETN therapy-ETN reference product (ETN-RP) or LBEC0101-between 2015 and 2021. Serum ETN levels were measured using liquid chromatography-tandem mass spectrometry. RESULTS: The 1-year continuation rates of ETN-RP and LBEC0101 were 58.7% and 74.4%, respectively. Effectiveness of treatment was evaluated in 18 patients; both products significantly reduced the 28-joint RA disease activity score and erythrocyte sedimentation rate (DAS28-ESR). Moreover, to determine equivalence, we analysed 11 patients who switched from ETN-RP to LBEC0101; the DAS28-ESR and serum ETN levels before and after switching were not significantly different. CONCLUSIONS: This real-world cohort study confirmed that the biosimilar of ETN, LBEC0101, was comparable to the reference product in terms of continuation rate, effectiveness at initiation of introduction, and effect persistence before and after switching in clinical practice.

Access to Document (DOI)

Clinical characteristics of cryopyrin-associated periodic syndrome and long-term real-world efficacy and tolerability of canakinumab in Japan: results of a nationwide survey.

Miyamoto T, Izawa K, Masui S, Yamazaki A, Yamasaki Y, Matsubayashi T, Shiraki M, Ohnishi H, Yasumura J, Tomohiro K, Miyamae T, Matsubara T, Arakawa N, Ishige T, Takizawa T, Shimbo A, Shimizu M, Kimura N, Maeda Y, Maruyama Y, Shigemura T, Furuta J, Sato S, Tanaka H, Izumikawa M, Yamamura M, Hasegawa T, Kaneko H, Nakagishi Y, Nakano N, Iida Y, Nakamura T, Wakiguchi H, Hoshina T, Kawai T, Murakami K, Akizuki S, Morinobu A, Ohmura K, Eguchi K, Sonoda M, Ishimura M, Furuno K, Kashiwado M, Mori M, Kawahata K, Hayama K, Shimoyama K, Sasaki N, Ito T, Umebayashi H, Omori T, Nakamichi S, Dohmoto T, Hasegawa Y, Kawashima H, Watanabe S, Taguchi Y, Nakaseko H, Iwata N, Kohno H, Ando T, Ito Y, Kataoka Y, Saeki T, Kaneko U, Murase A, Hattori S, Nozawa T, Nishimura K, Nakano R, Watanabe M, Yashiro M, Nakamura T, Komai T, Kato K, Honda Y, Hiejima E, Yonezawa A, Bessho K, Okada S, Ohara O, Takita J, Yasumi T, Nishikomori R, Japan CAPS working group

Arthritis & rheumatology (Hoboken, N.J.) (Arthritis and Rheumatology) 76 ( 6 ) 949 - 962 2024.01

Research paper (scientific journal), Joint Work, Accepted, ISSN 2326-5191

Objective: We assess the clinical characteristics of patients with cryopyrin-associated periodic syndrome (CAPS) in Japan and evaluate the real-world efficacy and safety of interleukin-1 (IL-1) inhibitors, primarily canakinumab. Methods: Clinical information was collected retrospectively, and serum concentrations of canakinumab and cytokines were analyzed. Results: A total of 101 patients were included, with 86 and 15 carrying heterozygous germline and somatic mosaic mutations, respectively. We identified 39 mutation types, and the common CAPS-associated symptoms corresponded with those in previous reports. Six patients (5.9% of all patients) died, with four of the deaths caused by CAPS-associated symptoms. Notably, 73.7% of patients (100%, 79.6%, and 44.4% of familial cold autoinflammatory syndrome, Muckle–Wells syndrome, and chronic infantile neurological cutaneous articular syndrome/neonatal onset multisystem inflammatory disease, respectively) achieved complete remission with canakinumab, and early therapeutic intervention was associated with better auditory outcomes. In some patients, canakinumab treatment stabilized the progression of epiphysial overgrowth and improved height gain, visual acuity, and renal function. However, 23.7% of patients did not achieve inflammatory remission with crucial deterioration of organ damage, with two dying while receiving high-dose canakinumab treatment. Serological analysis of canakinumab and cytokine concentrations revealed that the poor response was not related to canakinumab shortage. Four inflammatory nonremitters developed inflammatory bowel disease (IBD)—unclassified during canakinumab treatment. Dual biologic therapy with canakinumab and anti–tumor necrosis factor-α agents was effective for IBD– and CAPS-associated symptoms not resolved by canakinumab monotherapy. Conclusion: This study provides one of the largest epidemiologic data sets for CAPS. Although early initiation of anti–IL-1 treatment with canakinumab is beneficial for improving disease prognosis, some patients do not achieve remission despite a high serum concentration of canakinumab. Moreover, IBD may develop in CAPS after canakinumab treatment. (Figure presented.).

Access to Document (DOI)

Serum Leucine-rich Alpha-2 Glycoprotein Can be a Biomarker for Selecting Anti-Cytokine Biologics in Patients with Inflammatory Bowel Disease: A Multicentre Prospective Cohort Study

Amano, T; Yoshihara, T; Shinzaki, S; Sakakibara, Y; Yamada, T; Osugi, N; HIyama, S; Murayama, Y; Ogiyama, H; Nagaike, K; Tujii, Y; Asakura, A; Tashiro, T; Tani, M; Otake-Kasamoto, Y; Inoue, T; Yonezawa, A; Iijima, H; Hayashi, Y; Takehara, T

JOURNAL OF CROHNS & COLITIS 18 I1248 - I1248 2024.01

Research paper (scientific journal), Joint Work, Accepted, ISSN 1873-9946

Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series.

Takashi Masuda, Taro Funakoshi, Takahiro Horimatsu, Shinya Yamamoto, Takeshi Matsubara, Sho Masui, Shunsaku Nakagawa, Yasuaki Ikemi, Motoko Yanagita, Manabu Muto, Tomohiro Terada, Atsushi Yonezawa

Cancer chemotherapy and pharmacology (Cancer Chemotherapy and Pharmacology) 94 ( 4 ) 615 - 622 2024

Research paper (scientific journal), Joint Work, Last author, Corresponding author, Accepted, ISSN 03445704

PURPOSE: Proteinuria can cause interindividual variability in the pharmacokinetics of therapeutic antibodies and may affect therapeutic efficacy. Here, we measured the serum and urinary concentrations of bevacizumab (BV) and nivolumab (NIVO) in patients with proteinuria and reported a case series of these patients. METHODS: Thirty-two cancer patients who received BV every 3 weeks or NIVO every 2 weeks between November 2020 and September 2021 at Kyoto University Hospital were enrolled in this study. The serum and urinary concentrations of BV and NIVO were measured using liquid chromatography-tandem mass spectrometry. RESULTS: We divided the BV-treated patients and the NIVO-treated patients into two groups based on the urine protein-creatinine ratio (UPCR): UPCR 1 g/g or higher (BV, n = 9; NIVO, n = 3) and UPCR less than 1 g/g (BV, n = 14; NIVO, n = 6). Serum concentrations of the therapeutic antibodies adjusted by their doses were significantly lower in both BV- and NIVO-treated patients with UPCR 1 g/g or higher compared to those with less than 1 g/g. In patients with UPCR 1 g/g or higher, urinary concentrations of the therapeutic antibodies adjusted by their serum concentrations and urinary creatinine concentrations tended to increase. CONCLUSION: This case-series study suggests a possibility of reduction in serum concentrations of BV and NIVO in patients with proteinuria by urinary excretion of these drugs.

A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis

Ayumi Tsuzawa, Yoshiki Katada, Keisuke Umemura, Mitsuhiro Sugimoto, Asami Nishikawa, Yu-ki Sato, Yuko Yoshida, Norikai Kitada, Atsushi Yonezawa, Daisuke Nakajima, Hiroshi Date, Tomohiro Terada

Journal of Pharmaceutical Health Care and Sciences (Japanese Society of Pharmaceutical Health Care and Sciences) 9 ( 1 ) 12 2023.12

Research paper (scientific journal), Joint Work, Accepted, ISSN 2055-0294

Background: Drug-drug interaction management is complex. Nirmatrelvir/ritonavir is a potent cytochrome P450 (CYP) 3A inhibitor and influences pharmacokinetics of co-administered drugs. Although there are several reports about drug-drug interactions of nirmatrelvir/ritonavir, an influence of a concomitant use of nirmatrelvir/ritonavir and another potent CYP3A inhibitor on tacrolimus remains unclear. Here, we experienced a lung transplant patient with the novel coronavirus disease 2019 (COVID-19). In this patient, nirmatrelvir/ritonavir was administered, and the inhibitory effect of itraconazole on CYP3A was prolonged. Case presentation: We present a case in forties who had undergone lung transplantation. He was administered itraconazole and tacrolimus 1.0 mg/d, with a trough value of 8–12 ng/mL. The patient contracted the COVID-19, and a nirmatrelvir/ritonavir treatment was initiated. During the antiviral treatment, tacrolimus administration was discontinued for 5 d. Tacrolimus was resumed at 1.0 mg/d after completion of the nirmatrelvir/ritonavir treatment, but the trough value after 7 d was high at 31.6 ng/mL. Subsequently, the patient was placed on another 36-h tacrolimus discontinuation, but the trough value decreased to only 16.0 ng/mL. Conclusions: Co-administration of ritonavir caused a prolonged decrease in tacrolimus clearance through its inhibitory effects on CYP3A in a patient taking itraconazole. Management of drug-drug interaction by pharmacists can be important for patients with multiple medications.

Access to Document (DOI)

Acute inhibition of AMPA receptors by perampanel reduces amyloid β-protein levels by suppressing β-cleavage of APP in Alzheimer's disease models.

Sakiho Ueda, Akira Kuzuya, Masayoshi Kawata, Kohei Okawa, Chika Honjo, Takafumi Wada, Mizuki Matsumoto, Kazuya Goto, Masakazu Miyamoto, Atsushi Yonezawa, Yasuto Tanabe, Akio Ikeda, Ayae Kinoshita, Ryosuke Takahashi

FASEB journal : official publication of the Federation of American Societies for Experimental Biology (FASEB Journal) 37 ( 11 ) e23252 2023.11

Research paper (scientific journal), Joint Work, Accepted, ISSN 08926638

Hippocampal hyperexcitability is a promising therapeutic target to prevent Aβ deposition in AD since enhanced neuronal activity promotes presynaptic Aβ production and release. This article highlights the potential application of perampanel (PER), an AMPA receptor (AMPAR) antagonist approved for partial seizures, as a therapeutic agent for AD. Using transgenic AD mice combined with in vivo brain microdialysis and primary neurons under oligomeric Aβ-evoked neuronal hyperexcitability, the acute effects of PER on Aβ metabolism were investigated. A single oral administration of PER rapidly decreased ISF Aβ40 and Aβ42 levels in the hippocampus of J20, APP transgenic mice, without affecting the Aβ40 /Aβ42 ratio; 5 mg/kg PER resulted in declines of 20% and 31%, respectively. Moreover, PER-treated J20 manifested a marked decrease in hippocampal APP βCTF levels with increased FL-APP levels. Consistently, acute treatment of PER reduced sAPPβ levels, a direct byproduct of β-cleavage of APP, released to the medium in primary neuronal cultures under oligomeric Aβ-induced neuronal hyperexcitability. To further evaluate the effect of PER on ISF Aβ clearance, a γ-secretase inhibitor was administered to J20 1 h after PER treatment. PER did not influence the elimination of ISF Aβ, indicating that the acute effect of PER is predominantly on Aβ production. In conclusion, acute treatment of PER reduces Aβ production by suppressing β-cleavage of amyloid-β precursor protein effectively, indicating a potential effect of PER against Aβ pathology in AD.

Access to Document (DOI)

Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

Ando, Y; Nishiyama, H; Shimodaira, H; Takano, N; Sakaida, E; Matsumoto, K; Nakanishi, K; Sakai, H; Tsukamoto, S; Komine, K; Yasuda, Y; Kato, T; Fujiwara, Y; Koyama, T; Kitamura, H; Kuwabara, T; Yonezawa, A; Okumura, Y; Yakushijin, K; Nozawa, K; Goto, H; Matsubara, T; Hoshino, J; Yanagita, M

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (International Journal of Clinical Oncology) 28 ( 10 ) 1315 - 1332 2023.10

Research paper (scientific journal), Joint Work, Accepted, ISSN 1341-9625

Cisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance) < 45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (tumor lysis syndrome). Preventative rasburicase is recommended in high-risk cases of TLS. Thrombotic microangiopathy could be triggered by anticancer drugs and there is no evidence of efficacy of plasma exchange therapy. When proteinuria occurs during treatment with anti-angiogenic agents or multi-kinase inhibitors, dose reductions or interruptions based on grading should be considered. Grade 3 proteinuria and renal dysfunction require urgent intervention, including drug interruption or withdrawal, and referral to a nephrologist should be considered. The first-line drugs used for blood pressure elevation due to anti-angiogenic agents are ACE (angiotensin-converting enzyme) inhibitors and ARBs (angiotensin receptor blockers). The protein binding of drugs and their pharmacokinetics are considerably altered in patients with hypoalbuminemia. The clearance of rituximab is increased in patients with proteinuria, and the correlation with urinary IgG suggests similar pharmacokinetic changes when using other antibody drugs. AIN (acute interstitial nephritis) is the most common cause of ICI (immune checkpoint inhibitor)-related kidney injury that is often treated with steroids. The need for renal biopsy in patients with kidney injury that occurs during treatment with ICI remains controversial.

Access to Document (DOI)

Serum Concentrations of Infliximab and IL-6 for Predicting One-Year Discontinuation of Infliximab Treatment Owing to Secondary Non-response in Patients with Rheumatoid Arthritis.

Sho Masui, Atsushi Yonezawa, Miyuki Nakamura, Akira Onishi, Motomu Hashimoto, Hideo Onizawa, Takayuki Fujii, Kosaku Murakami, Koichi Murata, Masao Tanaka, Kotoko Yokoyama, Noriko Iwamoto, Takashi Shimada, Kotaro Itohara, Daiki Hira, Shunsaku Nakagawa, Satoshi Imai, Takayuki Nakagawa, Makoto Hayakari, Shuichi Matsuda, Akio Morinobu, Tomohiro Terada, Kazuo Matsubara

Biological & pharmaceutical bulletin (The Pharmaceutical Society of Japan) 46 ( 8 ) 1112 - 1119 2023.08

Research paper (scientific journal), Joint Work, Corresponding author, Accepted, ISSN 09186158

Secondary non-response to infliximab (IFX) occurs in some patients with rheumatoid arthritis (RA). Although therapeutic drug monitoring (TDM) is a useful tool to optimize IFX therapy, it is unclear whether it can help to identify the risk of secondary non-response. This study aimed to explore the utility of serum levels of IFX or other biomarkers to predict IFX discontinuation owing to secondary non-response. A single-center, retrospective study was conducted using the Kyoto University Rheumatoid Arthritis Management Alliance cohort database between 2011 and 2020. Serum IFX levels were measured using liquid chromatography-tandem mass spectrometry. An electrochemiluminescence assay was used to quantify serum levels of tumor necrosis factor-α and interleukin-6 and detect anti-drug antibodies. Eighty-four out of 310 patients were eligible for this study. The cutoff levels of biomarkers were determined by receiver operating characteristic analysis. IFX persistence was similar between groups stratified using IFX levels, tumor necrosis factor-α levels, interleukin-6 levels, and anti-drug antibodies positivity. The group with lower IFX and higher interleukin-6 levels had the worst therapy persistence (p = 0.017) and the most frequent disease worsening (90.0%, p < 0.001). Evaluating both interleukin-6 and IFX levels, not just IFX alone, enabled us to identify patients at risk of discontinuing IFX treatment. These findings support the utility of measuring IFX and interleukin-6 levels for successful maintenance therapy for RA.

医薬品情報を利活用したがん薬物療法に対する薬学的介入　タクロリムスとアプレピタントの薬物相互作用に着目し薬学的支援を行った皮膚筋炎併発胃がんの1例

川上恵, 北田徳昭, 米澤淳, 岡村みや子, 尾崎淳子, 池見泰明, 中川俊作, 今井哲司, 中川貴之, 土井恵太郎, 秋月修治, 武藤学, 寺田智祐

医薬品情報学 ((一社)日本医薬品情報学会) 25 ( 2 ) 83 - 90 2023.08

Research paper (scientific journal), Joint Work, Accepted, ISSN 1345-1464

医薬品情報を利活用した癌薬物療法に対する薬学的介入として、薬剤師がタクロリムスとアプレピタントの薬物相互作用に着目し薬学的支援を行った、皮膚筋炎併発胃癌患者の症例(70代男性)について報告した。薬剤師が収集した既知情報、文献的考察および定量評価結果を医師に示し、医師と治療レジメンおよび制吐療法を協議した。その結果、本患者が男性であること、および年齢が70代であり、催吐性リスクが必ずしも高くないことに鑑み、アプレピタントの使用は必須でないと判断された。これらの協議内容を踏まえ、総合的に判断した。その結果、制吐療法としてアプレピタントを使用せず、SOX療法を施行することが決定された。その結果、化学療法開始後の嘔気はコントロール可能な範囲であり、タクロリムスのアドヒアランスに影響はなかった。本症例のように、エビデンスや情報が少ないケースであっても、薬剤師が相互作用という単一的要因だけでなく、特定の背景を有する患者側に起因する複数の因子を同時に考慮し、情報収集、評価、提案およびモニタリングを行うことが、安全で適切な化学療法の提供つながることが示唆された。

Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.

Satoru Muto, Takeshi Matsubara, Takamitsu Inoue, Hiroshi Kitamura, Kazuhiro Yamamoto, Taisuke Ishii, Masahiko Yazawa, Ryohei Yamamoto, Naoto Okada, Kiyoshi Mori, Hiroyuki Yamada, Takashige Kuwabara, Atsushi Yonezawa, Takuya Fujimaru, Haruna Kawano, Hideki Yokoi, Kent Doi, Junichi Hoshino, Motoko Yanagita

International journal of clinical oncology (International Journal of Clinical Oncology) 28 ( 10 ) 1259 - 1297 2023.06

Research paper (scientific journal), Joint Work, Accepted, ISSN 1341-9625

The prevalence of CKD may be higher in patients with cancer than in those without due to the addition of cancer-specific risk factors to those already present for CKD. In this review, we describe the evaluation of kidney function in patients undergoing anticancer drug therapy. When anticancer drug therapy is administered, kidney function is evaluated to (1) set the dose of renally excretable drugs, (2) detect kidney disease associated with the cancer and its treatment, and (3) obtain baseline values for long-term monitoring. Owing to some requirements for use in clinical practice, a GFR estimation method such as the Cockcroft-Gault, MDRD, CKD-EPI, and the Japanese Society of Nephrology's GFR estimation formula has been developed that is simple, inexpensive, and provides rapid results. However, an important clinical question is whether they can be used as a method of GFR evaluation in patients with cancer. When designing a drug dosing regimen in consideration of kidney function, it is important to make a comprehensive judgment, recognizing that there are limitations regardless of which estimation formula is used or if GFR is directly measured. Although CTCAEs are commonly used as criteria for evaluating kidney disease-related adverse events that occur during anticancer drug therapy, a specialized approach using KDIGO criteria or other criteria is required when nephrologists intervene in treatment. Each drug is associated with the different disorders related to the kidney. And various risk factors for kidney disease associated with each anticancer drug therapy.

Access to Document (DOI)

【抗体医薬の進歩と課題】臨床における最新動向　抗体医薬品の血中濃度モニタリング

米澤淳

医学のあゆみ (医歯薬出版(株)) 285 ( 10 ) 960 - 964 2023.06

Lead author, Last author, Corresponding author, Accepted, ISSN 0039-2359

薬物血中濃度モニタリング(TDM)は抗菌薬,抗てんかん薬,免疫抑制薬などの個別化医療に大きく貢献してきた.抗体医薬品は免疫原性を有し血中濃度の個人差も現れることから,TDMの導入が期待されている.近年,関節リウマチ患者におけるインフリキシマブ血中濃度評価が承認された.しかし,低分子医薬品と同じように有効域を目指した投与設計を行うわけではなく,どのように実臨床で活用していくかの課題が残る.従来のproactive TDMに加えて,イベント発生時に行うreactive TDMという考え方も生まれ,抗体医薬品TDMの新しい考え方か展開されていく.また,抗体医薬品の革新的な分析手法の開発や,バイオトランスフォーメーションのエビデンスも蓄積されており,さらなる研究展開が進んでいる.本稿では,抗体医薬品のTDMの現状と今後の展望を概説するとともに,抗体医薬品の測定法の開発についてもも述べる.(著者抄録)

【気になるがん治療の最新Topics】がん治療におけるバイオシミラー

米澤淳

薬事 ((株)じほう) 65 ( 6 ) 1082 - 1086 2023.05

Lead author, Last author, Corresponding author, Accepted, ISSN 0016-5980

＜Key Point＞●バイオシミラーは先行バイオ医薬品と有効成分がまったく同じものではないため,同等性・同質性を検証する品質評価や臨床試験を実施して開発されている。●バイオ医薬品は高額であるため,バイオシミラーの使用は医療費削減に貢献する。●バイオシミラーのさらなる使用促進が課題である。●より良いバイオシミラーの開発が期待される。(著者抄録)

　 Previous page - Next page 　